Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy Volunteers - Martin, David E.; Blum, Robert; Wilton, John; Doto, Judy; Galbraith, Hal; Burgess, Gina L.; Smith, Philip C.; Ballow, Charles (Antimicrobial Agents and Chemotherapy, 2007)
Keywords: Adolescent; Adult; Anti-HIV Agents; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - adverse effects; Anti-HIV Agents - pharmacokinetics; Antibiotics. Antiinfectious agents. Antiparasitic agents; Area Under Curve; Biological and medical sciences; Dose-Response Relationship, Drug; Double-Blind Method; Human immunodeficiency virus; Human viral diseases; Humans; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunopathology; Infectious diseases; Male; Medical sciences; Middle Aged; Pharmacology; Pharmacology. Drug treatments; Succinates; Succinates - administration & dosage; Succinates - adverse effects; Succinates - pharmacokinetics; Triterpenes; Triterpenes - administration & dosage; Triterpenes - adverse effects; Triterpenes - pharmacokinetics; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Human; Immunopathology; Antiretroviral agent; Healthy subject; Toxicity; Retroviridae; AIDS; Bevirimat; Immune deficiency; Lentivirus; Infection; Virus; Viral disease; Antiviral; Inhibitor; Human immunodeficiency virus; Pharmacokinetics